The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Dose-adjusted (DA)-EPOCH-R with high-dose methotrexate (HD-MTX) for newly diagnosed stage II-IV CD5-positive diffuse large B-cell Iymphoma (CD5+ DLBCL): Primary analysis of PEARL5 study.
 
Kana Miyazaki
Honoraria - Celgene; Chugai Pharma; Kyowa Hakko Kirin
Research Funding - Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Nippon Shinyaku (Inst); Novartis (Inst); Novo Nordisk (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shionogi (Inst); Sumitomo Group (Inst); Takeda (Inst); Teijin Pharma (Inst); Toyama Chemical Co (Inst)
 
Naoko Asano
Honoraria - Celgene; Chugai Pharma; Takeda
 
Tomomi Yamada
No Relationships to Disclose
 
Kohta Miyawaki
No Relationships to Disclose
 
Hirotaka Takasaki
No Relationships to Disclose
 
Tadahiko Igarashi
Honoraria - Chugai Pharma; Kyowa Hakko Kirin
Research Funding - Celltrion (Inst); Eisai (Inst); Sanofi (Inst); SymBio Pharmaceuticals (Inst); Zenyaku Kogyo (Inst)
 
Momoko Nishikori
Honoraria - Chugai Pharma; Eisai; Janssen; Kyowa Hakko Kirin; Merck; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Eisai
 
Kinya Ohata
Honoraria - Kyowa Hakko Kirin; Mochida Pharmaceutical Co. Ltd.; Novartis; Shionogi
 
Kazutaka Sunami
Honoraria - Bristol-Myers Squibb; Celgene; Ono Pharmaceutical
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); MSD (Inst); Sanofi (Inst); Takeda (Inst)
 
Isao Yoshida
Honoraria - Celgene; Chugai Pharma; Kyowa Hakko Kirin; Mundipharma; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst)
 
Yuki Nishimura
No Relationships to Disclose
 
Satoshi Tamaru
Honoraria - Kinoshokuhin kenkyusyo; Kyowa Hakko Kirin
 
Masakatsu Nishikawa
Honoraria - Daiichi Sankyo
 
Koji Izutsu
Honoraria - Abbvie; Abbvie; Asahi Kasei; Astellas Pharma; Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Gilead Sciences; Janssen; Kyowa Hakko Kirin; Meiji Seika Kaisha; Mundipharma; Nihon Medi-Physics; Novartis; Ono Pharmaceutical; Otsuka; Shionogi; Takeda
Consulting or Advisory Role - Bayer; Celgene
Research Funding - Abbvie; Amgen; Astellas Pharma; Bayer; Celgene; Celltrion; Chugai Pharma; Daiichi Sankyo; Eisai; HUYA Bioscience International; Janssen; Ono Pharmaceutical; Sanofi; Solasia Pharma; SymBio Pharmaceuticals; Takeda; Zenyaku Kogyo
 
Tomohiro Kinoshita
Honoraria - Chugai Pharma; Eisai; Gilead Sciences; Janssen; Kyowa Hakko Kirin; Ono Pharmaceutical; Takeda; Zenyaku Kogyo
Research Funding - Chugai Pharma; Gilead Sciences; Solasia Pharma
 
Junji Suzumiya
Honoraria - Bristol-Myers Squibb; Celgene; Chugai/Roche; Eisai; Janssen; Kyowa Hakko Kirin; Takeda
Consulting or Advisory Role - Abbvie; Celgene; Janssen
Research Funding - Chugai/Roche; Eisai; Kyowa Hakko Kirin; Pfizer; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda
 
Koichi Ohshima
Honoraria - Chugai Pharma; Kyowa Hakko Kirin
Consulting or Advisory Role - SRS Acquiom
Research Funding - Chugai Pharma; Kyowa Hakko Kirin
 
Koji Kato
Honoraria - Celgene; Chugai Pharma; Janssen; Kyowa Hakko Kirin; MSD; Mundipharma; Ono Pharmaceutical; Sumitomo Group; Takeda
Research Funding - Abbvie; Celgene; Chugai Pharma; Eisai; Janssen; Kyowa Hakko Kirin; Novartis; Ono Pharmaceutical; Takeda
 
Naoyuki Katayama
Honoraria - Alexion Pharmaceuticals; Astellas Pharma; Bristol-Myers Squibb; Celgene; Chugai Pharma; Janssen; Kyowa Hakko Kirin; Nippon Shinyaku; Novartis; Novo Nordisk; Pfizer; Shionogi; Shire; Sumitomo Group; Sysmex; Taisho Toyama Pharma; Takeda
Research Funding - Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Nippon Shinyaku (Inst); Novartis (Inst); Novo Nordisk (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shionogi (Inst); Sumitomo Group (Inst); Takeda (Inst); Teijin Pharma (Inst); Toyama Chemical Co (Inst)
 
Motoko Yamaguchi
Honoraria - Bristol-Myers Squibb; Celgene; Chugai Pharma; Eisai; Kyowa Hakko Kirin; Meiji Seika Kaisha; Nippon Shinyaku; Takeda; Teijin Pharma
Consulting or Advisory Role - ERYTECH Pharma
Research Funding - Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Nippon Shinyaku (Inst); Novartis (Inst); Novo Nordisk (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shionogi (Inst); Sumitomo Group (Inst); Takeda (Inst); Teijin Pharma (Inst); Toyama Chemical Co (Inst)